Successful Multimodality Management of Advanced Acinic Cell Carcinoma of The Parotid Gland: A Case Report
DOI:
https://doi.org/10.51601/ijhp.v6i3.713Abstract
Background Acinic cell carcinoma (ACC) is a rare malignant salivary gland tumor that predominantly arises in the parotid gland. Although generally considered a low-grade malignancy, locally advanced or recurrent disease presents significant therapeutic challenges because of its infiltrative behavior and the absence of standardized treatment strategies. Case Presentation: A 56-year-old man presented with a recurrent painful left submandibular mass three years after previous surgical excision. Magnetic resonance imaging demonstrated a large left parotid tumor with mandibular erosion. The patient underwent neoadjuvant transarterial chemoembolization (TACE), followed by wide tumor excision, radical neck dissection, and immediate deltopectoral flap reconstruction. Histopathological examination confirmed acinic cell carcinoma of the parotid gland with a pathological stage of ypT4aN0M0 (Stage IVA). The postoperative course was uneventful, with satisfactory wound healing and viable flap reconstruction. A second-stage flap division was successfully performed without complications. Conclusion: This case demonstrates that multimodality management incorporating neoadjuvant TACE, radical surgical resection, and reconstructive surgery can provide favorable short-term oncologic and functional outcomes in selected patients with advanced recurrent acinic cell carcinoma of the parotid gland. Multidisciplinary collaboration remains essential for individualized treatment planning in this rare malignancy.
Downloads
References
[1] H.-T. Do Quyen, N. M. Duc, H. X. Tuan, N.-H. T. Tu, N. A. Khoi, and P. X. Dung, “Acinic Cell Carcinoma of Parotid Gland,” Radiol. Case Reports, vol. 18, no. 6, pp. 2194–2198, 2023, doi: 10.1016/j.radcr.2023.03.017.
[2] S. Alvi, D. Chudek, and F. Limaiem, Parotid Cancer. StatPearls [Internet]: StatPearls Publishing, 2023. [Online]. Available: https://www.ncbi.nlm.nih.gov/books/NBK538340/
[3] T. Brambullo et al., “Current Surgical Therapy of Locally Advanced cSCC: From Patient Selection to Microsurgical Tissue Transplant. Review,” Front. Oncol., vol. 11, p. 783257, 2021, doi: 10.3389/fonc.2021.783257.
[4] L. Pérez-Santiago, D. Huntley Pascual, J. S. Sánchez Lara, M. Huerta, and D. Dorcaratto, “How to Integrate Surgery into the Multidisciplinary Treatment of Liver-Only Metastatic Colorectal Cancer,” Cancers (Basel)., vol. 18, no. 3, p. 489, 2026, doi: 10.3390/cancers18030489.
[5] A. Yıldız and O. Kınıkoğlu, “Clinicopathologic Determinants of Overall Survival in Adrenocortical Carcinoma: A SEER-Based Population Study,” Cancers (Basel)., vol. 18, no. 7, p. 1103, 2026, doi: 10.3390/cancers18071103.
[6] H. Sutanto, G. J. Adytia, E. Elisa, and U. Maimunah, “Advances in Transarterial Chemoembolization For Hepatocellular Carcinoma: Integration with Systemic Therapies and Emerging Treatment Strategies,” Cancer Pathog. Ther., vol. 4, no. 1, pp. 1–13, 2026, doi: 10.1016/j.cpt.2025.04.004.
[7] Y. Yokoyama et al., “Current Surgical Treatment Strategies and Ongoing Issues for Locally Recurrent Rectal Cancer,” Jpn. J. Clin. Oncol., vol. 55, no. 11, pp. 1217–1228, 2025, doi: 10.1093/jjco/hyaf127.
[8] C. V. Obleagă et al., “Multidisciplinary Management of Complicated Locally Advanced and Fungating Breast Cancer: A Narrative Review,” Cancers (Basel)., vol. 18, no. 14, p. 2254, 2026, doi: 10.3390/cancers18142254.
[9] T. J. Vogl, A. Tröger, S. Bernatz, T. Stöver, and H. Adwan, “Efficacy and Safety of Transarterial Chemoperfusion for Head and Neck Malignancies,” Radiol. Med., vol. 130, no. 8, pp. 1254–1262, 2025, doi: 10.1007/s11547-025-02039-2.
[10] M. Alonso-Espías, F. Pérez, M. Gracia, and I. Zapardiel, “Management of Bulky Tumors in Cervical Cancer: Limits of the Surgical Approach,” J. Clin. Med., vol. 14, no. 4, p. 1142, 2025, doi: 10.3390/jcm14041142.
[11] L. Liu, X. Zhou, L. Li, J. Yang, and M. Tan, “Advanced Radiotherapy and Systemic Therapy in Head and Neck Adenoid Cystic Carcinoma: Current Progress and Future Integrated Strategies,” Transl. Oncol., vol. 70, p. 102841, 2026, doi: 10.1016/j.tranon.2026.102841.
[12] G. Salzano et al., “Prognostic Factors and Survival Outcomes in Parotid Gland Mucoepidermoid Carcinoma: A Systematic Review with Meta-Analysis and Workflow Proposal,” Cancers (Basel)., vol. 18, no. 7, p. 1146, 2026, doi: 10.3390/cancers18071146.
[13] G. Yamashita et al., “A Case of Recurrent Metastatic Parotid Acinic Cell Carcinoma Responsive to Pembrolizumab,” In Vivo (Brooklyn)., vol. 36, no. 2, pp. 1047–1051, 2022, doi: 10.21873/invivo.12801.
[14] A. B. Asmara and K. A. Rizki, “Transarterial Chemoembolization (TACE) in a Rare Case of Residual Sebaceous Carcinoma of the Parotid Gland : A Case Study,” Asian J. Heal. Sci., vol. 5, no. 7, pp. 172–178, 2026, doi: https://doi.org/10.58631/ajhs.v5i7.336.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Christian O. Manginstar, Reinaldo Putra Hardian
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
